Brain 147 (11), 38633873
In some embodiments, formulations or compositions described herein provide a constant, sustained, extended, delayed or pulsatile rate of release of an active agent into the inner ear environment and thus avoid any variability in drug exposure in treatment of otic disorders
doi: 10.70389/PJPH.100002 530 ChenJChenXHoCL
Strategies to overcome antimicrobial resistance (AMR) making use of non-essential target inhibitors: a review
Schfer Z, Mathisen A, Thomsen TR, Rossing P, Kirketerp-Mller K: Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark
Data Charting Relevant information from each included study was extracted using a data charting form that captured the following fields: author(s), year of publication, country of origin, whether the combination was an add-on or simultaneously used, study population characteristics relevant to the outcomes, and sample size, study design, intervention or exposition type and details of these, comparator, outcomes and their specifics, adverse effects reports, and key findings related to the scoping review questions
